Insights for the development of specific kinase inhibitors by targeted structural genomics

Drug Discovery Today

Volumn 12, Issue 9-10, 2007, Pages 365-372

  Fedorov, Oleg ^a   Sundström, Michael ^a   Marsden, Brian ^a   Knapp, Stefan ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 6 [2 [4 [(4 FLUOROPHENYL)PHENYLMETHYLENE] 1 PIPERIDYL]ETHYL] 7 METHYL 5H THIAZOLO[3,2 A]PYRIMIDIN 5 ONE; 6 CYCLOHEXYLMETHOXY 2 (4 SULFAMOYLANILINO)PURINE; AAL 993; ALOISINE; ALSTERPAULLONE; AMINOPYRAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; AS 601245; BIM 1; BIM 9; CGP 74514A; DORAMAPIMOD; ELLIPTICINE; EMODIN; ERLOTINIB; FASUDIL; GEFITINIB; H 1152; INDIRUBIN; K 252A; K 252B; KENPAULLONE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; SB 218078; STAUROSPORINE; SU 11274; SU 11652; SU 9516; SUNITINIB; TG 003; TRIAZOLODIAMINE; TWS 119; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BIOTECHNOLOGY; CATALYSIS; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; HUMAN; INFLAMMATION; PHYLOGENY; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURAL GENOMICS;

DRUG DESIGN; GENOMICS; HUMANS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; TECHNOLOGY, PHARMACEUTICAL;

EID: 34247350792     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.03.006     Document Type: Review

References (46)

1. Chandonia J.M., and Brenner S.E. The impact of structural genomics: expectations and outcomes. Science 311 (2006) 347-351
2. Vieth M., et al. Kinomics: characterizing the therapeutically validated kinase space. Drug Discov. Today 10 (2005) 839-846
3. Cohen P. Protein kinases-the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 1 (2002) 309-315
4. Faivre S., et al. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin. Oncol. 33 (2006) 407-420
5. Vieth M., et al. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 1697 (2004) 243-257
6. Liu B.A., et al. The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling. Mol. Cell 22 (2006) 851-868
7. Garrido-Hernandez H., et al. Design and synthesis of phosphotyrosine peptidomimetic prodrugs. J. Med. Chem. 49 (2006) 3368-3376
8. Vu C.B. Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70. Curr. Med. Chem. 7 (2000) 1081-1100
9. Barnett S.F., et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385 (2005) 399-408
10. Manning G., et al. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
11. Rellos P., et al. Structure and regulation of the human NEK2 centrosomal kinase. J. Biol. Chem. 282 (2007) 6833-6842
12. Capra M., et al. Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res. 66 (2006) 8147-8154
13. Boudeau J., et al. Emerging roles of pseudokinases. Trends Cell Biol. 16 (2006) 443-452
14. Brown N.R., et al. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J. Biol. Chem. 274 (1999) 8746-8756
15. Zhang X., et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125 (2006) 1137-1149
16. Sicheri F., et al. Crystal structure of the Src family tyrosine kinase Hck. Nature 385 (1997) 602-609
17. Sicheri F., and Kuriyan J. Structures of Src-family tyrosine kinases. Curr. Opin. Struct. Biol. 7 (1997) 777-785
18. Shen K., et al. Protein kinase structure and function analysis with chemical tools. Biochim. Biophys. Acta 1754 (2005) 65-78
19. Vogtherr M., et al. NMR characterization of kinase p38 dynamics in free and ligand-bound forms. Angew Chem. Int. Ed. Engl. 45 (2006) 993-997
20. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
21. Ashburn T.T., and Thor K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3 (2004) 673-683
22. Vedadi M., et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 15835-15840
23. Matulis D., et al. Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry 44 (2005) 5258-5266
24. Bullock A.N., et al. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. J. Med. Chem. 48 (2005) 7604-7614
25. Kroe R.R., et al. Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors. J. Med. Chem. 46 (2003) 4669-4675
26. Mayhood T.W., and Windsor W.T. Ligand binding affinity determined by temperature-dependent circular dichroism: cyclin-dependent kinase 2 inhibitors. Anal. Biochem. 345 (2005) 187-197
27. Kervinen J., et al. Effect of construct design on MAPKAP kinase-2 activity, thermodynamic stability and ligand-binding affinity. Arch. Biochem. Biophys. 449 1-2 (2006) 47-56
28. Okram B., et al. A general strategy for creating "inactive-conformation" abl inhibitors. Chem. Biol. 13 (2006) 779-786
29. Liu Y., and Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2 (2006) 358-364
30. Schindler T., et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000) 1938-1942
31. Pargellis C., et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9 (2002) 268-272
32. Wan P.T., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAFm. Cell 116 (2004) 855-867
33. Manley P.W., et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim. Biophys. Acta 1697 (2004) 17-27
34. Gill A.L., et al. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 48 (2005) 414-426
35. Cumming J.G., et al. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. 14 (2004) 5389-5394
36. Heron N.M., et al. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. 16 (2006) 1320-1323
37. Oliver A.W., et al. Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO J. 25 (2006) 3179-3190
38. Eswaran J., et al. Crystal structures of thep21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Structure 15 (2007) 201-213
39. Muraki M., et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J. Biol. Chem. 279 (2004) 24246-24254
40. Louie A.Y., and Meade T.J. Metal complexes as enzyme inhibitors. Chem. Rev. 99 (1999) 2711-2734
41. Zhang L., et al. Ruthenium complexes as protein kinase inhibitors. Org. Lett. 6 (2004) 521-523
42. Bregman H., et al. An organometallic inhibitor for glycogen synthase kinase 3. J. Am. Chem. Soc. 126 (2004) 13594-13595
43. Williams D.S., et al. Switching on a signaling pathway with an organoruthenium complex. Angew. Chem. Int. Ed. Engl. 44 (2005) 1984-1987
44. Debreczeni J.E., et al. Ruthenium half-sandwich complexes bound to protein kinase pim-1. Angew. Chem. Int. Ed. Engl. 45 (2006) 1580-1585
45. Smalley K.S., et al. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res. 67 (2007) 209-217
46. Abagyan R., et al. Disseminating structural genomics data to the public: from a data dump to an animated story. Trends Biochem. Sci. 31 (2006) 76-78